Theravance Biopharma shares target cut by H.C. Wainwright

Investment firm H.C. Wainwright has adjusted its price target for Theravance Biopharma (NASDAQ: NASDAQ:TBPH), reducing it to $15 from the previous $20, while still maintaining a Buy rating on the stock.

The firm's decision follows Theravance's recent report of second-quarter financial results that fell short of expectations.

Theravance Biopharma reported second-quarter revenue of $14.3 million, which was below both the analyst's projection of $15.5 million and the Street consensus of $15.4 million.

The company's net sales of Yupelri, recognized by Viatris (VTRS; not rated), were $54.5 million for the quarter, marking a 1% year-over-year decline.

The management attributed the decrease in Yupelri sales to a combination of factors, including channel mix and a lower realized net price. This drop in sales has prompted H.C. Wainwright to revise its price target for Theravance Biopharma.

In addition to the lower revenue figures, the firm also noted that the anticipated launch of ampreloxetine, one of Theravance's developmental programs, has been delayed.

The updated timing for this program, as provided by the company's management, was a factor in the decision to lower the price target to $15.

Theravance Biopharma reported an 18% year-over-year increase in net sales for its leading product, YUPELRI, in the first quarter of 2024. Hospital doses sold also saw a significant rise of 31% compared to the previous year. With $100 million in cash reserves and no debt, the company is well-positioned for future developments, including potential expansion into the Chinese market through a partnership with Viatris.

InvestingPro Insights

As investors digest the latest financial results and price target adjustments for Theravance Biopharma, it's worth considering a few key metrics and insights from InvestingPro. The company's market capitalization currently stands at approximately $466.39 million, reflecting the market's valuation of the firm. Notably, Theravance Biopharma holds more cash than debt on its balance sheet, which could provide some financial flexibility in navigating its current challenges. Additionally, despite the recent setbacks, analysts have revised their earnings upwards for the upcoming period, signaling potential confidence in the company's future performance.

It's also important to highlight that the company's revenue has shown growth over the last twelve months, with a 26.65% increase as of Q1 2024. This growth trajectory, coupled with the fact that analysts predict the company will be profitable this year, may offer some reassurance to investors concerned about the recent dip in stock price. Furthermore, the company's liquid assets exceed its short-term obligations, which could be a critical factor in weathering any near-term financial storms.

For those seeking more in-depth analysis, there are additional InvestingPro Tips available that could shed further light on Theravance Biopharma's financial health and stock potential. These tips can be found at https://www.investing.com/pro/TBPH, offering a more comprehensive view of the company's financial landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.